PleoPharma Lands $6.5M NIDA Grant for Phase 3 Trial

PleoPharma announced that the National Institute on Drug Abuse, part of the National Institutes of Health, awarded the company a $6.5M grant over three years. The company says the funding will support CAN-004, its pivotal Phase 3 study of PP-01 for cannabis withdrawal symptoms in adults with cannabis use disorder.

This is a funding story, but not a venture-capital story. PleoPharma is adding federal research support to a late-stage clinical program after previously announcing a $17.5M Series A and a $36M Series B. The real milestone is not the check alone. It is the chance to generate evidence in a category where the patient population is large, the withdrawal burden is clinically meaningful, and no medication has FDA approval for cannabis withdrawal syndrome or cannabis use disorder.

The market implication is uncomfortable and important. Cannabis has moved rapidly toward normalization, while the treatment infrastructure for people who become dependent has not kept pace. PleoPharma is betting that withdrawal is not a side note to recovery but one of the mechanisms that can pull patients back into use.

What Happened

In an August 20, 2026 announcement, PleoPharma said NIDA awarded the company $6.5M over three years under award number 1U01DA0660079-1. The company said the grant will help advance CAN-004, an ongoing Phase 3 study evaluating PP-01 in adults with moderate to severe cannabis use disorder who want to discontinue cannabis use.

The ClinicalTrials.gov record for CAN-004 independently confirms that the study is recruiting and sponsored by PleoPharma. The registry describes a randomized, quadruple-masked, placebo- and active-controlled Phase 3 trial with an estimated 420 participants. It lists an actual study start of June 17, 2026, estimated primary completion in July 2027, and estimated study completion in September 2027.

The award announcement is current enough that NIH RePORTER had not indexed the disclosed award number when checked on August 20. That timing gap does not disprove the company announcement, but it does mean the award amount and term should be attributed to PleoPharma until the government record becomes searchable.

Why This Matters

The clinical need is bigger than the cultural conversation often admits. The 2024 National Survey on Drug Use and Health supports PleoPharma's cited estimate that roughly 20.6M people in the United States had cannabis use disorder in 2024. Many people can use cannabis without developing dependence, but population-level normalization does not erase the smaller group facing anxiety, irritability, sleep disruption, cravings, and other withdrawal symptoms when they try to stop.

There is currently no FDA-approved medication for cannabis withdrawal syndrome or cannabis use disorder. That leaves behavioral support and clinical judgment carrying a burden that drug development has not yet answered. PP-01 is designed to address withdrawal symptoms directly, which could matter because early discomfort can undermine a person's ability to remain engaged in treatment.

The grant also changes the financing mix. A venture round asks private investors to price risk and eventual return. A federal research award puts public dollars behind the production of evidence. Neither source makes Phase 3 easier, but the combination gives PleoPharma more runway to answer a question that the market has not solved.

The PP-01 Clinical Program

PP-01 remains investigational and is not FDA approved. PleoPharma describes it as a once-daily oral product with a dual mechanism, while the Phase 3 registry identifies it as a combination product involving CB1 partial agonism and GABAergic modulation. CAN-004 includes nabilone as an active comparator and placebo as another comparator, making the pivotal program a test of both efficacy and what happens as treatment tapers.

PleoPharma says the prior Phase 2b CAN-002 study met its primary endpoint, demonstrated a dose response, and reported no serious adverse events. The company has also reported specific improvements in irritability and angry outbursts from a 2026 scientific presentation. Those results are encouraging company-reported findings, but Phase 3 is where the evidence must become durable enough for regulatory review.

The company announced FDA Fast Track designation for PP-01 in February 2025. Fast Track can increase opportunities for communication with FDA and potentially support faster review mechanisms, but it is not an approval, an efficacy verdict, or a substitute for pivotal data.

Who Is Building PleoPharma

PleoPharma says it was founded in 2019 by physicians Ginger Constantine, M.D. and Jay Constantine, M.D. after they observed people struggling with significant discomfort while trying to discontinue cannabis. That origin story gave the company a narrow clinical thesis: if withdrawal contributes to relapse, treating withdrawal may help more patients continue recovery efforts.

The current management page lists Ginger Constantine as CEO, co-founder, and chairperson of the board, and Jay Constantine as CMO, co-founder, and director. Shelli Graham, Ph.D. serves as SVP, Medical/Clinical Research. The grant announcement misspells Graham's surname as “Grahm,” but PleoPharma's management page and prior company releases consistently use “Graham.”

The company lists offices in Phoenixville, Pennsylvania, and Boca Raton, Florida. Its principal business address also appears in an SEC Form D filing, providing a regulatory cross-check on the corporate identity behind the program.

Capital Before the Grant

PleoPharma's public financing trail shows a company steadily buying down clinical risk. It announced a $17.5M Series A in June 2023, led by DynaGrow Capital and MintPharma Capital, to fund the Phase 2b program. In October 2025, the company announced a $36M Series B intended to advance PP-01 into Phase 3, although it did not name the investors in that round.

The $6.5M NIDA award sits beside those equity financings rather than replacing them. Drug development consumes capital in layers: trial sites, enrollment, manufacturing, monitoring, statistics, regulatory work, and the unglamorous systems that keep a pivotal study credible. The grant gives PleoPharma another funding source for that machinery without changing the central fact that CAN-004 still has to produce convincing results.

What This Signals

PleoPharma's award signals that cannabis withdrawal is entering a more serious phase of clinical development. The policy debate around cannabis has often focused on criminalization, access, taxes, and consumer markets. Addiction medicine has a different job: identify where use becomes disorder, measure the harm, and test interventions without moral theater.

For biotech operators, the story is also a reminder that financing strategy can follow scientific milestones instead of chasing one giant round. PleoPharma used its Series A for Phase 2b, raised a larger Series B for Phase 3, and now says federal funding will support the pivotal program. Each source of capital is attached to a more expensive standard of proof.

The next meaningful update will not be another clever description of unmet need. It will be enrollment progress, trial execution, and eventually data from CAN-004. Until then, PP-01 is a promising investigational program with public research support, a verified Phase 3 registry, and a very real obligation to prove that the medicine can match the size of the problem.